Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 9, 2007, Pages 2060-2066

  Hauser, Dominik R J ^a   Scior, Thomas ^c   Domeyer, David M ^a   Kammerer, Bernd ^b   Laufer, Stefan A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; ML 3163; PURINE DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; DRUG DESIGN; DRUG SYNTHESIS; ENERGY TRANSFER; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; INHIBITION KINETICS; PREDICTION;

ADENOSINE TRIPHOSPHATE; BINDING SITES; DRUG DESIGN; HYDROPHOBICITY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BINDING; PURINONES; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 34247574138     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061061w     Document Type: Article

References (48)

1. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discovery 2003, 2, 717-726.
2. Johnson, G. L.; Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298, 1911-1912.
3. Smolen, J. S.; Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discovery 2003, 2, 473-488.
4. Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem 2002, 2, 1011-1020.
5. Laufer, S. A.; Wagner, G. K. From Imidazoles to Pyrimidines: New Inhibitors of Cytokine Release. J. Med. Chem. 2002, 45, 2733-2740.
6. Cohen, P. The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 1999, 3, 459-465.
7. Bellon, S.; Fitzgibbon, M. J.; Fox, T.; Hsiao, H. M.; Wilson, K. P. The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation. Structure Fold. Des. 1999, 7, 1057-1065.
8. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
9. Traxler, P. Tyrosine kinase inhibitors in cancer treatment (part II). Expert Opin. Ther. Pat. 1998, 8, 1599-1625.
10. Laufer, S. A.; Domeyer, D. M.; Scior, T. R.; Albrecht, W.; Hauser, D. R. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J. Med. Chem. 2005, 48, 710-722.
11. Wan, Z.; Boehm, J. C.; Bower, M. J.; Kassis, S.; Lee, J. C.; Zhao, B.; Adams, J. L. N-Phenyl-N-purin-6-yl ureas: The design and synthesis of p38a MAP kinase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 1191-1194.
12. Hanke, J. H.; Gardner, J. P.; Dow, R. L.; Changelian, P. S.; Brissette, W. H.; Weringer, E. J.; Pollok, B. A.; Connelly, P. A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 1996, 271, 695-701.
13. Liu, Y.; Bishop, A.; Witucki, L.; Kraybill, B.; Shimizu, E.; Tsien, J.; Ubersax, J.; Blethrow, J.; Morgan, D. O.; Shokat, K. M. Structural basis for selective inhibition of Src family kinases by PP1. Chem. Biol. 1999, 6, 671-678.
14. Zhu, X.; Kim, J. L.; Newcomb, J. R.; Rose, P. E.; Stover, D. R.; Toledo, L. M.; Zhao, H.; Morgenstern, K. A. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 1999, 7, 651-661.
15. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371, 199-204.
16. Cohen, P.; Goedert, M. Engineering protein kinases with distinct nucleotide specificities and inhibitor sensitivities by mutation of a single amino acid. Chem. Biol. 1998, 5, R161-R164.
17. Doytchinova, I.; Petrova, S. \"N6-N7\" - a modification of the \"N6-C8\" model for the binding site on adenosine A1 receptors with improved steric and electrostatic fit. Med. Chem. Res. 1998, 8, 143-152.
18. Cocuzza, A. J.; Chidester, D. R.; Culp, S.; Fitzgerald, L.; Gilligan, P. Use of the Suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists. Bioorg. Med. Chem. Lett. 1999, 9, 1063-1066.
19. Davoll, J. Pyrrolo[2,3-d]pyrimidines. J. Chem. Soc., Abstr. 1960, 131-138.
20. Staab, H. A. Syntheses with heterocyclic amides (azolides). Angew. Chem. 1962, 74, 407-23.
21. Mazzanti, A.; Lunazzi, L.; Minzoni, M.; Anderson, J. E. Rotation in biphenyls with a single ortho-substituent. J. Org. Chem. 2006, 71, 5474-5481.
22. Bott, G.; Field, L. D.; Sternhell, S. Steric effects. A study of a rationally designed system. J. Am. Chem. Soc. 1980, 102, 5618-5626.
23. Laufer, S.; Thuma, S.; Peifer, C.; Greim, C.; Herweh, Y.; Albrecht, A.; Dehner, F. An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. Anal. Biochem. 2005, 135-137.
24. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Structural basis for p38a MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol. 2003, 10, 764-769.
25. MOE. Chemical Computing Group Inc. Montreal, 2004.
26. Halgren, T. A. Maximally diagonal force constants in dependent angle-bending coordinates. II. Implications for the design of empirical force fields. J. Am. Chem. Soc. 1990, 112, 4710-4723.
27. Gasteiger, J.; Marsili, M. Prediction of proton magnetic resonance shifts: the dependence on hydrogen charges obtained by iterative partial equalization of orbital electronegativity. Org. Magn. Reson. 1981, 75, 353-360.
28. Sanner, M. F. Python: A programming language for software integration and development. J. Mol. Graphics Modell. 1999, 17, 57-61.
29. Michel, F. Sanner; Daniel Stoffler; Arthur, J. Olson ViPEr a Visual Programming Environment for Python. Presented at the 10th International Python Conference, Feb 4-7, 2002. (http:// www.scripps.edu/~sanner/html/papers/IPC02. pdf).
30. Weiner, S. J.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. An all atom force field for simulations of proteins and nucleic acids. J. Comput. Chem. 1986, 7, 230-252.
31. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic-algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 79, 1639-1662.
32. Sybyl 7.0. Tripos Inc. St.Louis, MO, 2004.
33. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
34. Muegge, I.; Martin, Y. C. A General and Fast Scoring Function for Protein-Ligand Interactions: A Simplified Potential Approach. J. Med. Chem. 1999, 42, 791-804.
35. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
36. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
37. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
38. Pearlman, D. A.; Charifson, P. S. Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system. J. Med. Chem. 2001, 44, 3417-3423.
39. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. Development and use of quantum mechanical molecular models. 76. AMI: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
40. Stewart, J. J. P. Semiempirical molecular orbital methods. In Reviews in Computational Chemistry; VCH Publishers: New York, 1990; Volume 1, pp 45-81
41. Nowak, W.; Wietzbowska, M. A theoretical study of geometry and transition moment directions of flexible fluorescent probes - Acetoxy derivatives of phenylanthracene. THEOCHEM 1996, 368, 223-234.
42. Testa, A. C. Hydrogen bonding and the protonated water dimer. Spectrosc. Lett. 1999, 32, 819-828.
43. Bures, M.; Bezus, J. Study of hydrogen bonding in carboxylic acids by the MNDO/M method. Collect. Czech. Chem. Commun. 1994, 59, 1251-1260.
44. Masunov, A.; Dannenberg, J. J. Theoretical study of urea and thiourea. 2. Chains and ribbons. J. Phys. Chem. B 2000, 104, 806-810.
45. Stahl, M.; Rarey, M. Detailed Analysis of Scoring Functions for Virtual Screening. J. Med. Chem. 2001, 44, 1035-1042.
46. InsightII 2000. Accelrys Inc. San Diego, CA, 2000.
47. Connolly, M. L. Solvent-accessible surfaces of proteins and nucleic acids. Science 1983, 221, 709-713.
48. Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: An analysis of ALOGP and CLOGP methods. J. Phys. Chem. A 1998, 102, 3762-3772.